Everything below concerns immunomodulatory peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
== Further reading == The American Food Journal. American Food Journal, Incorporated. 1921. pp. 11–12. Retrieved May 23, 2017. Peter, K.V. (2004). Handbook of Herbs and Spices. Handbook of Herbs and Spices. CRC Press. p. 280. ISBN 978-1-85573-721-1. Retrieved May 24, 2017. Lovegren, S. (2005). Fashionable Food: Seven Decades of Food Fads. University of Chicago Press. p. 228. ISBN 978-0-226-49407-4. Retrieved May 23, 2017. Davis, E.L. (2009). Encyclopedia of Contemporary Chinese Culture. Encyclopedias of Contemporary Culture Series. Routledge. p. 385. ISBN 978-0-415-77716-2. Retrieved May 24, 2017. Solt, G. (2014). The Untold History of Ramen: How Political Crisis in Japan Spawned a Global Food Craze. California Studies in Food and Culture. University of California Press. p. 113. ISBN 978-0-520-27756-4. Retrieved May 24, 2017. Mehta, Foram (August 12, 2016). "New Research Shows Instant Noodles are Especially Harmful for Women". India.com. Retrieved May 24, 2017.
=== Luna Diabetes === Former founders of Timesulin, Welldoc, Companion Medical and Bigfoot Biomedical have joined together to create the world's first automated insulin delivery system for those that want to continue to use insulin pens. The team is calling it Episodic AID. The working product name is Luna.
=== No development reported === AB-101 (RJ-101) – topical – alopecia – undefined mechanism of action BRM-421 (GPN-00136, PDSP) – topical – alopecia – cell proliferation stimulant Dimethylcurcumin (ASC-J9, AJ-101) – topical – male pattern baldness – androgen receptor degradation enhancer Lepzacitinib (ATI-1777) – topical – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 3 inhibitor PF-277343 – unspecified – alopecia – undefined mechanism of action Research programme: janus kinase inhibitors - Aclaris Therapeutics/ JAKPharm – unknown – alopecia areata – Janus kinase 3 inhibitors Research programme: skin diseases therapeutics - Quark Pharmaceuticals (QP-AL1; QP-AL2) – unknown – alopecia (chemotherapy-induced) – RNA interference Research programme: stem cell therapeutics - Histostem (Cirrhosis HMScs) – unknown – alopecia – cell replacement Synephrine (AB-102) – topical – alopecia – α1-adrenergic receptor agonist Valproic acid (VPA spray) – topical – male pattern baldness – glycogen synthase kinase 3β inhibitor, Wnt signalling pathway stimulant
== Platforms == Current nanoparticle drug delivery systems can be cataloged based on their platform composition into several groups: polymeric nanoparticles, inorganic nanoparticles, viral nanoparticles, lipid-based nanoparticles, and nanoparticle albumin-bound (nab) technology. Each family has its unique characteristics.
It is injected once a month, after the first month having a double dose. The main reported side effects are injection site reactions, although there are a growing number of reports of severe side effects from a minority of patients. Approved by the FDA in February 2020, ubrogepant (Ubrelvy) is an oral medication manufactured by AbbVie. Also approved that month, eptinezumab (Vyepti), is an intravenous migraine prophylactic medication manufactured by Lundbeck. Rimegepant (Nurtec ODT) subsequently became the first oral CGRP receptor antagonist to be approved by the FDA for both acute migraine treatment (approved February 2020) and prevention of episodic migraine (approved June 2021). It is manufactured by Pfizer. In September 2021 the FDA approved Qulipta (atogepant), the first oral CGRP receptor antagonist approved to prevent chronic migraine. The phytocannabinoids delta-9 tetrahydrocannabinol (Δ9-THC) and its oxidative byproduct cannabinol (CBN) are found to induce a CB1 and CB2 cannabinoid receptor-independent release of calcitonin gene-related peptide from capsaicin-sensitive perivascular sensory nerves, an action that other psychotropic cannabinoids cannot do.
Sources: en.wikipedia.org
The Golgi matrix is a protein scaffold around the Golgi apparatus made up of Golgins, GRASP's and miscellaneous other proteins on the cytoplasmic side of the Golgi apparatus involved in keeping its shape and membrane stacking.
=== Names === Vortioxetine was previously sold under the brand name Brintellix in the United States, but in May 2016, the US Food and Drug Administration (FDA) approved a name change to Trintellix in order to avoid confusion with the blood-thinning medication Brilinta (ticagrelor). Other brand names include Torvox, Vantaxa, Voxigain, Trivoxetin, Vipca, Vortica, Vatoin, Xomat, Vortidif.
=== First House passage === Following markups by various House committees on their relevant portions of the bill, the House Budget Committee met on May 16, 2025, to combine the various markups into a single reconciliation bill. Some fiscally conservative Republicans opposed the bill over a desire for greater spending cuts, and the bill was rejected in a 21–16 vote, with representatives Chip Roy of Texas, Ralph Norman of South Carolina, Andrew Clyde of Georgia, and Josh Brecheen of Oklahoma joining all Democratic committee members to vote against it. Republican Lloyd Smucker of Pennsylvania changed his vote from yes to no so that he would be allowed to bring a motion to reconsider the bill at a later time. On May 18, the Budget Committee voted to advance the bill in a 17–16 vote. Roy, Norman, Clyde, and Brecheen changed their votes to present after House Republican leadership agreed to make Medicaid work requirements—previously scheduled to begin in 2029—kick in sooner and decrease future subsidies for clean energy. Despite this, the four Republicans said they would not support the bill's final passage unless more changes were made. Republicans did not secure these votes until May 21, when the bill was amended. On the morning of May 22, the United States House of Representatives passed OBBBA by a vote of 215–214–1, mostly along party lines. Fiscally conservative Republicans Thomas Massie and Warren Davidson broke from their party to vote against the bill. Freedom Caucus chair Andy Harris of Maryland voted present.
Acapulco, with its natural harbor, had been settled by indigenous peoples for thousands of years and later established as a port by Hernán Cortés in 1523. By Humboldt’s visit, the city had diminished in significance, with a small population and little commercial activity. Upon arrival, Humboldt used his instruments to correct geographic errors caused by local currents and earthquakes, further improving navigation and mapping accuracy. Humboldt’s primary reason for coming to New Spain was to secure passage to the Philippines, but he viewed Mexico as a vital subject for study. At the start of the nineteenth century, New Spain was a populous and prosperous colony, contributing significantly to Spain’s economy through silver, gold, and agricultural production. Humboldt, holding a royal passport, enjoyed unprecedented access to official records and facilities, enabling him to study the country’s economic and political structures thoroughly.
Sources: en.wikipedia.org
== Commercial performance == In the United States, the album debuted at #4 on the Billboard 200 chart behind Travis Scott's JackBoys 2 and Justin Bieber's Swag with 118,000 album-equivalent units, matching the debut of Lord Willin' (2002) and simultaneously marking the duo's second ever top-10 album. Of those 118,000 album-equivalent units, 58,000 were pure album sales and 59,000 were from streaming services, marking Clipse's biggest streaming week ever with 77.49 million on-demand streams of the album's tracks. Elsewhere, the album debuted at #1 on the Billboard Independent Albums chart, and charted top-10 placements in Switzerland and Canada.
Upon the film's release to YouTube it garnered thousands of views very quickly, but the film's exposure was skyrocketed when Valve, developers of the Half-Life series, promoted it with a news post on Steam. It was quickly featured on many popular gaming news websites and had surpassed 1 million views within two days of release. As of 2 October 2013, parts one and two have 5 million and 1.1 million views on YouTube respectively.
Dutasteride has been found to be significantly more effective than finasteride in the treatment of scalp hair loss in men, which has been attributed to its more complete inhibition of 5α-reductase and by extension decrease in DHT production. In addition to their antiandrogenic uses, 5α-reductase inhibitors have been found to reduce adverse affective symptoms in premenstrual dysphoric disorder in women. This is thought to be due to prevention by 5α-reductase inhibitors of the conversion of progesterone into allopregnanolone during the luteal phase of the menstrual cycle. 5α-Reductase inhibitors are sometimes used as a component of feminizing hormone therapy for transgender women in combination with estrogens and/or other antiandrogens. They may have beneficial effects limited to improvement of scalp hair loss, body hair growth, and possibly skin symptoms such as acne. However, little clinical research on 5α-reductase inhibitors in transgender women has been conducted, and evidence of their efficacy and safety in this group is limited. Moreover, 5α-reductase inhibitors have only mild and specific antiandrogenic activity, and are not recommended as general antiandrogens. 5α-Reductase inhibitors have minimal side effects and are well tolerated in both men and women. In men, the most common side effect is sexual dysfunction (0.9–15.8% incidence), which may include decreased libido, erectile dysfunction, and reduced ejaculate. Another side effect in men is breast changes, such as breast tenderness and gynecomastia (2.8% incidence).
The borders of SR Bosnia and Herzegovina were almost identical to those that the Condominium of Bosnia and Herzegovina had during the period of Austro-Hungarian rule that lasted until 1918. That year Bosnia became part of the Kingdom of Serbs, Croats, and Slovenes and divided into several banovinas (regional administrative units), namely parts of Vrbas, Drina, Zeta and Croatia banovinas. With the establishment of a People's Republic, its modern borders were delineated.
== Drugs withdrawn == The following therapeutic drugs were withdrawn from the market primarily because of hepatotoxicity: Troglitazone, bromfenac, trovafloxacin, ebrotidine, nimesulide, nefazodone, ximelagatran and pemoline.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.